Comparative Pharmacology
Head-to-head clinical analysis: FML versus PRED MILD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FML versus PRED MILD.
FML vs PRED MILD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Agonist at glucocorticoid receptors, leading to inhibition of phospholipase A2 via annexin-1 induction, reducing prostaglandin and leukotriene synthesis; also suppresses cytokine production and inflammatory cell migration.
Prednisolone acetate is a corticosteroid that binds to the glucocorticoid receptor, leading to inhibition of phospholipase A2 and reduction of inflammatory mediators such as prostaglandins and leukotrienes.
Fluorometholone ophthalmic suspension 0.1%: Instill 1 drop into conjunctival sac 2-4 times daily. In severe conditions, may increase to 1 drop every hour initially.
1 to 2 drops in the affected eye(s) every hour during the day and every 2 hours at night until a favorable response is obtained, then reduce to 1 drop every 4 hours, and later to 1 drop 3 to 4 times daily as needed to control symptoms.
None Documented
None Documented
The terminal elimination half-life of fluorometholone is approximately 1.5 hours in plasma. Clinically, this short half-life allows for multiple daily dosing; however, ocular administration results in sustained local effects due to corneal binding.
The terminal elimination half-life of prednisolone is approximately 2.1-3.5 hours. Clinically, this short half-life supports once-daily dosing for many conditions, with minimal accumulation upon repeated administration.
FML (fluorometholone) is primarily metabolized in the liver, with metabolites excreted renally. Approximately 70-80% of the dose is eliminated in urine as metabolites, with less than 5% as unchanged drug. Fecal excretion accounts for about 10%.
Prednisolone is primarily excreted renally, with approximately 70-80% of the dose eliminated as metabolites in urine (including glucuronides and sulfates) and less than 10% as unchanged drug. Biliary/fecal excretion accounts for about 20% of the dose.
Category C
Category C
Ophthalmic Corticosteroid
Ophthalmic Corticosteroid